News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Novo Nordisk A/S to Restart Liraglutide Obesity Studies
June 23, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Novo Nordisk (NOVOb.CO) will re-launch late-stage trials of its new diabetes drug liraglutide for treating obesity, the company said on Tuesday in a vote of confidence in the drug that has overcome safety concerns.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Novo Nordisk
MORE ON THIS TOPIC
IN PARTNERSHIP WITH TRUVETA
Webinar: AI for Faster, More Precise Real-World Research: Extracting Clinical Notes Data at Scale
August 27, 2025
·
1 min read
·
BioSpace Insights
Regulatory
The US Is Losing Its Biopharma Edge, Writes Former FDA Commissioner
August 27, 2025
·
3 min read
·
Dan Samorodnitsky
Rare diseases
Regeneron Eyes 2026 Filing for siRNA Myasthenia Gravis Drug After Phase III Win
August 27, 2025
·
2 min read
·
Tristan Manalac
Podcast
Lilly’s Obesity Pill Heads to the FDA, AbbVie Bets on Psychedelics, HHS Unveils More Change
August 27, 2025
·
1 min read
·
Jef Akst
